CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · Real-Time Price · USD
45.96
-1.30 (-2.75%)
Nov 21, 2024, 11:09 AM EST - Market open
CRISPR Therapeutics AG Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 202.83 | 371.21 | 1.2 | 914.96 | 0.72 | 289.59 | Upgrade
|
| Revenue Growth (YoY) | 19.31% | 30885.48% | -99.87% | 127154.94% | -99.75% | 9169.85% | Upgrade
|
| Cost of Revenue | 463.89 | 517.58 | 571.9 | 441.75 | 269.41 | 179.36 | Upgrade
|
| Gross Profit | -261.06 | -146.38 | -570.7 | 473.22 | -268.69 | 110.23 | Upgrade
|
| Selling, General & Admin | 71.33 | 76.16 | 102.46 | 99.69 | 85.75 | 63.49 | Upgrade
|
| Operating Expenses | 71.33 | 76.16 | 102.46 | 99.69 | 85.75 | 63.49 | Upgrade
|
| Operating Income | -332.4 | -222.54 | -673.16 | 373.53 | -354.44 | 46.74 | Upgrade
|
| Interest & Investment Income | 95.92 | 71.82 | 22.66 | 6 | - | 10.03 | Upgrade
|
| Earnings From Equity Investments | - | - | - | - | - | -5.47 | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | - | 6.38 | - | Upgrade
|
| EBT Excluding Unusual Items | -236.47 | -150.72 | -650.5 | 379.53 | -348.06 | 51.31 | Upgrade
|
| Other Unusual Items | - | - | - | - | - | 16 | Upgrade
|
| Pretax Income | -236.47 | -150.72 | -650.5 | 379.53 | -348.06 | 67.31 | Upgrade
|
| Income Tax Expense | 3.12 | 2.89 | -0.33 | 1.87 | 0.81 | 0.45 | Upgrade
|
| Earnings From Continuing Operations | -239.59 | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 | Upgrade
|
| Net Income | -239.59 | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 | Upgrade
|
| Net Income to Common | -239.59 | -153.61 | -650.18 | 377.66 | -348.87 | 66.86 | Upgrade
|
| Shares Outstanding (Basic) | 83 | 79 | 78 | 76 | 66 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 83 | 79 | 78 | 80 | 66 | 57 | Upgrade
|
| Shares Change (YoY) | 5.11% | 1.90% | -3.29% | 21.90% | 15.84% | 18.70% | Upgrade
|
| EPS (Basic) | -2.89 | -1.94 | -8.36 | 4.97 | -5.29 | 1.23 | Upgrade
|
| EPS (Diluted) | -2.90 | -1.94 | -8.36 | 4.70 | -5.29 | 1.17 | Upgrade
|
| Free Cash Flow | -191.2 | -269.85 | -532.93 | 457.27 | -256.72 | 49.99 | Upgrade
|
| Free Cash Flow Per Share | -2.31 | -3.41 | -6.85 | 5.69 | -3.89 | 0.88 | Upgrade
|
| Gross Margin | -128.71% | -39.43% | - | 51.72% | - | 38.06% | Upgrade
|
| Operating Margin | -163.88% | -59.95% | -56190.40% | 40.82% | -49295.55% | 16.14% | Upgrade
|
| Profit Margin | -118.13% | -41.38% | -54271.70% | 41.28% | -48520.86% | 23.09% | Upgrade
|
| Free Cash Flow Margin | -94.27% | -72.69% | -44484.89% | 49.98% | -35705.70% | 17.26% | Upgrade
|
| EBITDA | -313.08 | -202.7 | -648.99 | 391.48 | -345.25 | 51.47 | Upgrade
|
| EBITDA Margin | -154.36% | -54.61% | - | 42.79% | - | 17.77% | Upgrade
|
| D&A For EBITDA | 19.32 | 19.84 | 24.17 | 17.95 | 9.18 | 4.73 | Upgrade
|
| EBIT | -332.4 | -222.54 | -673.16 | 373.53 | -354.44 | 46.74 | Upgrade
|
| EBIT Margin | -163.88% | -59.95% | - | 40.82% | - | 16.14% | Upgrade
|
| Effective Tax Rate | - | - | - | 0.49% | - | 0.67% | Upgrade
|
| Revenue as Reported | 202.83 | 371.21 | 1.2 | 914.96 | 0.72 | 289.59 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.